Home › Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
 

Keywords :   


Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C

2013-04-22 13:30:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibbs investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1. Language:  English Contact HTML:  MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: c agreement trial combination

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Farm Progress America, May 20, 2024
20.05Farm Progress America, May 20, 2024
20.05Nielsen launches The Media Distributor Gauge
20.05Minerva AI Companion enhances the TV viewing experience
20.05Ryanair profits surge after fares climb by 20%
20.05SES Ethiosat delivering content to 95% of TV homes in Ethiopia
More »